Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.55 |
| ▸ | FABP3 | P05413 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cridanimod SCHEMBL3801665 | 1.00 | GLA (1.00) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL29373385 | 1.00 | GLA (1.00) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL27895128 | 0.98 | GLA (0.96) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL3375823 | 0.98 | GLA (0.96) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| Cridanimod SCHEMBL3375819 | 0.98 | GLA (0.96) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| SCHEMBL15732891 | 0.93 | GLA (0.87) | GLAKDM4EAPEX1P2RX4ALDH1A1 | |
| SCHEMBL29859932 | 0.90 | KDM4E (1.00) | GLAKDM4EAPEX1ALDH1A1POLB | |
| SCHEMBL150053 | 0.90 | KDM4E (1.00) | GLAKDM4EAPEX1ALDH1A1POLB | |
| SCHEMBL21027234 | 0.86 | GLA (0.74) | GLAKDM4EAPEX1P2RX4POLB | |
| SCHEMBL21027012 | 0.86 | GLA (0.74) | GLAKDM4EAPEX1P2RX4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186623-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| US-20250188143-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | FUNDACION PARA LA INVESTIGACION MEDICA APLICADA (ES) | 2025-06-12 | — | — | US | claimed |
| EP-4489795-A1 | EXPRESSION SYSTEM FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| EP-4489794-A1 | COMBINED GENE AND RADIO THERAPY FOR THE TREATMENT OF CANCER | Fundación para la Investigación Médica Aplicada (ES) | 2025-01-15 | — | — | EP | claimed |
| US-20240423927-A1 | COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY | INSTITUT CURIE (FR) | 2024-12-26 | — | — | US | claimed |
| CN-119173281-A | Expression system for treating cancer | 应用医学研究基金会 | 2024-12-20 | — | — | CN | claimed |
| CN-119110733-A | Gene and radiation combination therapy for the treatment of cancer | 应用医学研究基金会 | 2024-12-10 | — | — | CN | claimed |
| US-20240285755-A1 | Adjuvants | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-29 | — | — | US | claimed |
| CN-118284423-A | Combination therapy of STING agonists and cytokines | 免疫传感器治疗股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| EP-4373498-A2 | STING AGONIST COMBINATION TREATMENTS WITH CYTOKINES | Immunesensor Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| EP-1970372-B1 | SALTS OF 9-OXOACRIDINE-10-ACETIC ACID WITH 1-ALKYLAMNO-1-DESOXY-POLYOLS | EPHAG AS (EE) | 2010-11-03 | — | — | EP | claimed |
| US-20100144780-A1 | Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods | PJSC PHARMSYNTHEZ (RU) | 2010-06-10 | — | — | US | claimed |
| US-20100087399-A1 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER | SURKOV KIRILL GENNADIEVICH | 2010-04-08 | — | — | US | claimed |
| CN-101370783-A | Salts and mixtures of 9-oxoacridine-10-acetic acid and 1-alkylamino-1-deoxypolyols, pharmaceutical compositions containing same, and methods of treatment | EPHAG AS (EE) | 2009-02-18 | — | — | CN | claimed |
| WO-2008121029-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID AND/OR SALTS AND/OR ITS ESTERS THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF MALIGNANT TUMORS OF FEMALE REPRODUCTIVE SYSTEM | SURKOV KIRILL GENNEDIEVICH (RU) | 2008-10-09 | — | — | WO | claimed |
| WO-2008121028-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER | SURKOV KIRILL GENNEDIEVICH (RU) | 2008-10-09 | — | — | WO | claimed |
| EP-1970372-A2 | SALTS OF 9-OXOACRIDINE-10-ACETIC ACID WITH 1-ALKYLAMNO-1-DESOXY-POLYOLS | EPhaG AS (EE) | 2008-09-17 | — | — | EP | claimed |
| WO-2008024026-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR THE TREATMENT, PROPHYLAXIS OR RELAPSE PREVENTION OF PROSTATE CANCER | SURKOV KIRILL GENNADIEVICH (RU) | 2008-02-28 | — | — | WO | claimed |
| WO-2008024027-A2 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, ITS SALTS AND ESTERS FOR ENHANCING THE EFFICACY OF ANTIANDROGENIC TREATMENT | SURKOV KIRILL GENNADIEVICH (RU) | 2008-02-28 | — | — | WO | claimed |
| US-20060035848-A1 | Broad-spectrum inhibitor of viruses in the Flaviviridae family | ZYMETX, INC. | 2006-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285755-A1 | Adjuvants | STING1, TLR3, TLR9 | GLA 4100/4885KDM4E 3012/4885APEX1 925/4885 |
| US-20060035848-A1 | Broad-spectrum inhibitor of viruses in the Flaviviridae family | EIF2AK2, MAVS, EFTUD2 | GLA 1900/4885KDM4E 610/4885APEX1 3012/4885 |
| US-20100087399-A1 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER | ACR, APEH, CA9 | GLA 1751/4885KDM4E 2986/4885APEX1 175/4885 |
| US-20100144780-A1 | Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods | ADSL, ACMSD, ASS1 | GLA 153/4885KDM4E 3727/4885APEX1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.